107 research outputs found

    Development of Dual-Gain SiPM Boards for Extending the Energy Dynamic Range

    Full text link
    Astronomical observations with gamma rays in the range of several hundred keV to hundreds of MeV currently represent the least explored energy range. To address this so-called MeV gap, we designed and built a prototype CsI:Tl calorimeter instrument using a commercial off-the-shelf (COTS) SiPMs and front-ends which may serve as a subsystem for a larger gamma-ray mission concept. During development, we observed significant non-linearity in the energy response. Additionally, using the COTS readout, the calorimeter could not cover the four orders of magnitude in energy range required for the telescope. We, therefore, developed dual-gain silicon photomultiplier (SiPM) boards that make use of two SiPM species that are read out separately to increase the dynamic energy range of the readout. In this work, we investigate the SiPM's response with regards to active area (3×3 mm23\times3 \ \mathrm{mm}^2 and 1×1 mm21 \times 1 \ \mathrm{mm}^2) and various microcell sizes (1010, 2020, and 35 μm35 \ \mu \mathrm{m}). We read out 3×3×6 cm33\times3\times6 \ \mathrm{cm}^3 CsI:Tl chunks using dual-gain SiPMs that utilize 35 μm35 \ \mu \mathrm{m} microcells for both SiPM species and demonstrate the concept when tested with high-energy gamma-ray and proton beams. We also studied the response of $17 \times 17 \times 100 \ \mathrm{mm}^3CsIbarstohighenergyprotons.WiththeCOTSreadout,weestimate(withseveralassumptions)thatthedualgainprototypehasanenergyrangeof CsI bars to high-energy protons. With the COTS readout, we estimate (with several assumptions) that the dual-gain prototype has an energy range of 0.25-400 \ \mathrm{MeV}withthetwoSiPMspeciesoverlappingatarangeofaround with the two SiPM species overlapping at a range of around 2.5-30 \ \mathrm{MeV}$. This development aims to demonstrate the concept for future scintillator-based high-energy calorimeters with applications in gamma-ray astrophysics

    Development of a CsI Calorimeter for the Compton-Pair (ComPair) Balloon-Borne Gamma-Ray Telescope

    Full text link
    There is a growing interest in astrophysics to fill in the observational gamma-ray MeV gap. We, therefore, developed a CsI:Tl calorimeter prototype as a subsystem to a balloon-based Compton and Pair-production telescope known as ComPair. ComPair is a technology demonstrator for a gamma-ray telescope in the MeV range that is comprised of 4 subsystems: the double-sided silicon detector, virtual Frisch grid CdZnTe, CsI calorimeter, and a plastic-based anti-coincidence detector. The prototype CsI calorimeter is composed of thirty CsI logs, each with a geometry of 1.67×1.67×10 cm31.67 \times 1.67 \times 10 \ \mathrm{cm^3}. The logs are arranged in a hodoscopic fashion with 6 in a row that alternate directions in each layer. Each log has a resolution of around 8%8 \% full-width-at-half-maximum (FWHM) at 662 keV662 \ \mathrm{keV} with a dynamic energy range of around 250 keV30 MeV250\ \mathrm{keV}-30 \ \mathrm{MeV}. A 2×22\times2 array of SensL J-series SiPMs read out each end of the log to estimate the depth of interaction and energy deposition with signals read out with an IDEAS ROSSPAD. We also utilize an Arduino to synchronize with the other ComPair subsystems that comprise the full telescope. This work presents the development and performance of the calorimeter, its testing in thermal and vacuum conditions, and results from irradiation by 225 MeV2-25 \ \mathrm{MeV} monoenergetic gamma-ray beams. The CsI calorimeter will fly onboard ComPair as a balloon experiment in the summer of 2023

    On which timescales do gas transfer velocities control North Atlantic CO2 flux variability?

    Get PDF
    The North Atlantic is an important basin for the global ocean's uptake of anthropogenic and natural carbon dioxide (CO2), but the mechanisms controlling this carbon flux are not fully understood. The air-sea flux of CO2, F, is the product of a gas transfer velocity, k, the air-sea CO2 concentration gradient, ΔpCO2, and the temperature and salinity-dependent solubility coefficient, α. k is difficult to constrain, representing the dominant uncertainty in F on short (instantaneous to interannual) timescales. Previous work shows that in the North Atlantic, ΔpCO2 and k both contribute significantly to interannual F variability, but that k is unimportant for multidecadal variability. On some timescale between interannual and multidecadal, gas transfer velocity variability and its associated uncertainty become negligible. Here, we quantify this critical timescale for the first time. Using an ocean model, we determine the importance of k, ΔpCO2 and α on a range of timescales. On interannual and shorter timescales, both ΔpCO2 and k are important controls on F. In contrast, pentadal to multidecadal North Atlantic flux variability is driven almost entirely by ΔpCO2; k contributes less than 25%. Finally, we explore how accurately one can estimate North Atlantic F without a knowledge of non-seasonal k variability, finding it possible for interannual and longer timescales. These findings suggest that continued efforts to better constrain gas transfer velocities are necessary to quantify interannual variability in the North Atlantic carbon sink. However, uncertainty in k variability is unlikely to limit the accuracy of estimates of longer term flux variability

    Prospective randomized trial of iliohypogastric-ilioinguinal nerve block on post-operative morphine use after inpatient surgery of the female reproductive tract

    Get PDF
    <p>Abstract</p> <p>Objective</p> <p>To determine the impact of pre-operative and intra-operative ilioinguinal and iliohypogastric nerve block on post-operative analgesic utilization and length of stay (LOS).</p> <p>Methods</p> <p>We conducted a prospective randomized double-blind placebo controlled trial to assess effectiveness of ilioinguinal-iliohypogastric nerve block (IINB) on post-operative morphine consumption in female study patients (<it>n </it>= 60). Patients undergoing laparotomy via Pfannenstiel incision received injection of either 0.5% bupivacaine + 5 mcg/ml epinephrine for IINB (Group I, <it>n </it>= 28) or saline of equivalent volume given to the same site (Group II, <it>n </it>= 32). All injections were placed before the skin incision and after closure of rectus fascia via direct infiltration. Measured outcomes were post-operative morphine consumption (and associated side-effects), visual analogue pain scores, and hospital length of stay (LOS).</p> <p>Results</p> <p>No difference in morphine use was observed between the two groups (47.3 mg in Group I vs. 45.9 mg in Group II; <it>p </it>= 0.85). There was a trend toward lower pain scores after surgery in Group I, but this was not statistically significant. The mean time to initiate oral narcotics was also similar, 23.3 h in Group I and 22.8 h in Group II (<it>p </it>= 0.7). LOS was somewhat shorter in Group I compared to Group II, but this difference was not statistically significant (<it>p </it>= 0.8). Side-effects occurred with similar frequency in both study groups.</p> <p>Conclusion</p> <p>In this population of patients undergoing inpatient surgery of the female reproductive tract, utilization of post-operative narcotics was not significantly influenced by IINB. Pain scores and LOS were also apparently unaffected by IINB, indicating a need for additional properly controlled prospective studies to identify alternative methods to optimize post-surgical pain management and reduce LOS.</p

    Using vital statistics to estimate the population-level impact of osteoporotic fractures on mortality based on death certificates, with an application to France (2000-2004)

    Get PDF
    Abstract Background We developed a methodology using vital statistics to estimate the impact of osteoporotic fractures on the mortality of an entire population, and applied it to France for the period 2000-2004. Methods Current definitions of osteoporotic fractures were reviewed and their components identified. We used the International Classification of Diseases with national vital statistics data for the French adult population and performed cross-classifications between various components: age, sex, I-code (site) and E-code (mechanism of fracture). This methodology allowed identification of appropriate thresholds and categorization for each pertinent component. Results 2,625,743 death certificates were analyzed, 2.2% of which carried a mention of fracture. Hip fractures represented 55% of all deaths from fracture. Both sexes showed a similar pattern of mortality rates for all fracture sites, the rate increased with age from the age of 70 years. The E-high-energy code (present in 12% of death certificates with fractures) was found to be useful to rule-out non-osteoporotic fractures, and to correct the overestimation of mortality rates. Using this methodology, the crude number of deaths associated with fractures was estimated to be 57,753 and the number associated with osteoporotic fractures 46,849 (1.85% and 1.78% of all deaths, respectively). Conclusion Osteoporotic fractures have a significant impact on overall population mortality.</p

    The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN

    Get PDF
    Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by impaired mucociliary clearance leading to irreversible lung damage. In contrast to other rare lung diseases like cystic fibrosis (CF), there are only few clinical trials and limited evidence-based treatments. Management is mainly based on expert opinions and treatment is challenging due to a wide range of clinical manifestations and disease severity. To improve clinical and translational research and facilitate development of new treatments, the clinical trial network for PCD (PCD-CTN) was founded in 2020 under the framework of the European Reference Network (ERN)-LUNG PCD Core. Applications from European PCD sites interested in participating in the PCD-CTN were requested. Inclusion criteria consisted of patient numbers, membership of ERN-LUNG PCD Core, use of associated standards of care, experience in PCD and/or CF clinical research, resources to run clinical trials, good clinical practice (GCP) certifications and institutional support. So far, applications from 22 trial sites in 18 European countries have been approved, including >1400 adult and >1600 paediatric individuals with PCD. The PCD-CTN is headed by a coordinating centre and consists of a steering and executive committee, a data safety monitoring board and committees for protocol review, training and standardisation. A strong association with patient organisations and industrial companies are further cornerstones. All participating trial sites agreed on a code of conduct. As CTNs from other diseases have demonstrated successfully, this newly formed PCD-CTN operates to establish evidence-based treatments for this orphan disease and to bring new personalised treatment approaches to patients
    corecore